linjc16/ctgov huggingface dataset:
Pain Assessment in the Perioperative Area

Study Overview
=================
Brief Summary
-----------------
This study is mainly focusing on reducing the pain scores during IV cannulation in pediatric population in the preoperative period. Applying EMLA cream is a well-known fact world wide. we would like to study the effect of ultrasound waves in the penetration of the given drung into the skin so that we could achieve the effect of the drug quickly.

Detailed Description
-----------------
To assess the intensity of pain in children in the perioperative area during IV cannulation using a combination of EMLA cream and low-frequency USG probe. To assess the intensity of pain in children in the perioperative area during IV cannulation using a combination of EMLA cream and high-frequency USG probe and final comparison between these groups will assess the effect of ultrasound in the penetration of the drug into the skin.

Official Title
-----------------
Pain Assessment in the Perioperative Area During IV Cannulation Using a Combination of EMLA and Low-frequency USG Probe Versus a Combination of EMLA Cream and High-frequency Probe in Pediatric Cases- A Randomized Control Trial

Conditions
-----------------
Pain, Procedural

Intervention / Treatment
-----------------
* Device: IV cannulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All children in the preoperative period. Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention group<br>EMLA cream + High-frequency USG probe kept for 15minutes.After 15 minutes IV cannulation will be done and Pain intensity assessment will be done using Faces Pain Scale-Revised (FPS-R) | Device: IV cannulation<br>* IV cannulation in the preoperative period<br>|
| Active Comparator: Control group<br>EMLA cream+Low frequency USG probe kept over the cream for 15 minutes. IV cannulation will be done and Pain intensity assessment will be done using Faces Pain Scale-Revised (FPS-R) | Device: IV cannulation<br>* IV cannulation in the preoperative period<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare the intensity of pain among control versus interventional groups. Pain intensity assessment will be done using Faces Pain Scale-Revised (FPS-R) | to check the efficacy of high-frequency ultrasound probe in comparison to low-frequency probe in aiding the drug penetration there by decreasing the pain intensity during IV cannulation | 15minutes |
Ambu® Aura-ITM Versus Ambu Aura GainTM for Fiberoptic Intubation in Children

Study Overview
=================
Brief Summary
-----------------
The investigators test the hypothesis that fiberoptic intubation (time and success rate) differ between the Ambu® Aura-ITM and Ambu Aura GainTM in paralyzed anaesthetized pediatric patients

Official Title
-----------------
A Randomised Non Crossover Study Comparing Ambu® Aura-ITM and Ambu® Aura GainTM for Fiberoptic Intubation in Children

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Device: Ambu Aura GainTM
* Device: Ambu® Aura-ITM


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I-II age 1.5 - 6 years minor surgery extraglottic airway device Exclusion Criteria: age (<18 months, >6 years) weight (<10 kg, >20 kg) a known difficult airway risk of aspiration

Ages Eligible for Study
-----------------
Minimum Age: 18 Months
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Ambu® Aura-ITM<br> | Device: Ambu® Aura-ITM<br>* Time and success rate<br>|
| Active Comparator: Ambu Aura GainTM<br> | Device: Ambu Aura GainTM<br>* Time and success rate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fiberoptic intubation | The airway tube view was scored using an established scoring system (4=only vocal cords visible; 3=vocal cords plus posterior epiglottis; 2=vocal cords plus anterior epiglottis; 1=vocal cords not seen) | 5 minutes |
Vasodilator Free Measure of Fractional Flow Reserve

Study Overview
=================
Brief Summary
-----------------
Narrowing of coronary arteries interferes with blood flow and can cause chest pain. Cardiologists sometimes quantify the extent of the narrowing by measuring the fractional flow reserve (the ratio of the pressure in the aorta to the pressure downstream of the narrowing under conditions of maximal flow). We propose a new technique based on principles of wave intensity analysis (WIA) to better assess coronary stenosis and the significance of the narrowing without the need for administration of vasodilator agents such as adenosine. This would simplify assessment and improve our ability to advise patients whether stent treatment will help their symptoms.

Official Title
-----------------
ADenosine Vasodilator Independent Stenosis Evaluation Study (ADVISE)

Conditions
-----------------
Coronary Stenosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with coronary stenosis Exclusion Criteria: Patient's with cardiac pacemakers, valvular heart disease, and chronic renal failure Unable to consent Contraindications to adenosine Contraindications to cardiac MRI

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pressure and flow velocity<br> | |
| Pressure only<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation and descriptive characteristics between adenosine free measure of stenosis severity and FFR |  | Study end | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronary stenosis, Wave intensity analysis, Instantaneous Flow Reserve, iFR, Fractional Flow Reserve
How Menopause Affects Lipid Metabolism in the Visceral Fat Depots

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to describe the molecular mechanisms related to an increased visceral fat mass and changed T-cell homeostasis. the project is expected to add new knowledge to the field of metabolic diseases after menopause and increase the focus of how lipid affects the development of metabolic disease in relation to the menopausal transition.

Detailed Description
-----------------
The study is a cross sectional study including 60 women between 45 and 55 years of age. Investigators aim to include 20 premenopausal women, 20 postmenopausal women and 20 postmenopausal women taking hormone treatment (HT). All the women are going through gynecological surgery for benign reasons. During the operation investigators will take a visceral fat biopsy from the omentum. maximally 1 month before- or after the operation the subject will meet at the lab for further testing, including: Health examination Blood samples OGTT DXA scan VO2 max testing MRI of the abdomen hyperinsulinemic euglycemic clamp

Official Title
-----------------
How Menopause Affects Lipid Metabolism in the Visceral Fat Depots

Conditions
-----------------
Insulin Sensitivity and Lipid Metabolism

Intervention / Treatment
-----------------
* Other: This is an observational study. There are no interventions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women 45-55 years old for HT treated women (HT more than 1 year) Exclusion Criteria: Infections during the last month chronic disease claustrophobia smoking Alcoholic intake > 14 servings hysterectomy before menopause oophorectomized early menopause (before 40 yrs) BMI > 30

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Premenopausal<br>Premenopausal women going through gynecological surgery | Other: This is an observational study. There are no interventions<br> <br> |
| Postmenopausal<br>Postemnopausal women going through gynecological surgery | Other: This is an observational study. There are no interventions<br> <br> |
| Postmenopausal + HT<br>Postmenopausal women going through gynecological surgery who has been taking hormone treatment through the past year (as a minimum) | Other: This is an observational study. There are no interventions<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Insulin sensitivity | measured through a hyperinsulinemic euglycemic clamp (Outcome: glucose infusion rate) | 4 weeks |
Can CCTA Technicians Provide Accurate Interpretation of Findings in Patients Presenting to the ED in After Hours?

Study Overview
=================
Brief Summary
-----------------
Coronary Computed Tomographic Angiography (CCTA) is emerging as the diagnostic test of choice in chest pain patients with low to intermediate probability of coronary artery disease (CAD). Qualified CCTA readers may not be available around the clock in most centers, limiting the use of CCTA. This study aimed to determine if well-qualified CCTA technicians can provide initial accurate diagnosis to guide initial management and triage of such patients

Official Title
-----------------
Can CCTA Technicians Provide Accurate Interpretation of Findings in Chest Pain Patients Presenting to the Emergency Department in After Hours?

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Diagnostic Test: Coronary Computed Tomographic Angiography (CCTA)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients referred for elective CCTA to assess coronary artery disease Exclusion Criteria: Patients with previous coronary revascularization procedures (PCI or CABG).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Coronary Computed Tomographic Angiography (CCTA)|CCTA of coronary arteries|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The agreements between the two technicians and the cardiologist in evaluation of coronary segments | All coronary segments are independently assesses for CAD by the two technicians and the expert cardiologist | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CCTA interpretation, technicians, experts, comparison
Genomic Search for Childhood Obesity Genes-A Pilot Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to screen a pediatric population (ages 2-8) for genes associated with childhood obesity.

Detailed Description
-----------------
The incidence of childhood obesity has been growing at an epidemic rate for the past several years, in part due to the lack of understanding of mechanisms at a molecular level. This study will screen a healthy general pediatric population age 2 to 8 for potential genes associated with childhood obesity using whole genomic gene arrays. Patients with BMI values equal to or greater than the 85th percentile will be compared to patients with a BMI below or equal to the 15th percentile. The INSIG2 gene will be specifically studied because of its identification in several populations of obese subjects. The differences in gene expression of the 2 groups will then be used to identify new genes for investigation in childhood obesity.

Official Title
-----------------
Genomic Search for Childhood Obesity Genes-A Pilot Study

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Procedure: blood draws


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ages 2-8, predominately Caucasian to minimize population stratification Exclusion Criteria: Chronic diseases (diabetes, cancer, etc) and known syndromes

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: blood draws|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obesity
The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's Disease

Study Overview
=================
Brief Summary
-----------------
The purpose was to evaluate as to whether administration of infliximab of 12 week interval with supplementary VSL#3 is more effective or at least of similar efficacy when compared to conventional administration of infliximab only of 8 week interval.

Detailed Description
-----------------
The purpose of our study was to evaluate if supplementation of VSL#3 can improve treatment outcome for those pediatric Crohn's patients treated with infliximab every 12 weeks.

Official Title
-----------------
Reduction in Frequency of Infliximab Administration From q 8 Weeks to q 12 Weeks in Children With Crohn's Disease Receiving Probiotic VSL#3 Supplementation: A Pilot Study

Conditions
-----------------
Crohn's Disease

Intervention / Treatment
-----------------
* Dietary Supplement: VSL#3


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pediatric patients who were diagnosed with severe Crohn's disease who require infliximab treatment confirmed diagnostic of Crohn's disease in clinical, endoscopic and histological findings Exclusion Criteria: patients who has proven to have infliximab antibody

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Dietary Supplement: VSL#3|children with severe Crohn's disease were assigned in a 1:1 ratio with either IFX 5 mg/kg q 12 weeks + concurrent immunomodulator + VSL#3 (4 sachets of 450 x 109 organisms per day) (Group A), or IFX 5 mg/kg q 8 weeks + concurrent immunomodulator (Group B).|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction in Frequency of Infliximab Administration from q 8 Weeks to q 12 Weeks in Children with Crohn's Disease Receiving Probiotic VSL#3 Supplementation | Disease Activity Index (PCDAI) scores, hematocrit, albumin, ESR, CRP, TNF-α, IL-8, INF-γ, and endoscopic findings (Simple Endoscopic Score for Crohn's Disease was used) were assessed | 1-year treatment period | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Crohn's disease, VSL #3, infliximab
Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors

Study Overview
=================
Brief Summary
-----------------
Using whole blood samples and plasma samples obtained from some hemophilia A patients with inhibitors, the investigators will perform the coagulation assessment in the co-presence of aPCC and factor VIII by comprehensive coagulation assays and flow chamber analysis under blood flow conditions.

Detailed Description
-----------------
Comprehensive coagulation assays using recently popular rotational thromboelastometry (ROTEM), factor Xa/thrombin/plasmin generation test, and coagulation wave analysis and recently developed flow chamber system under blood flow conditions (T-TAS®) will be used. A bypassing agent, aPCC (Feiba®) and recombinant factor VIII (Advate®) will be added ex vivo to whole blood and plasma samples from patients with hemophilia A with inhibitors to compare with the coagulation effects of aPCC in the presence of factor VIII and those of aPCC in its absence under the conditions close to the physiological condition. Furthermore, the difference in the coagulation effects by the difference in inhibitor epitopes will be examined.

Official Title
-----------------
Basic Study on Novel Therapeutic Strategy With Bypassing Agent Therapy in Hemophilia A Patients With Inhibitors

Conditions
-----------------
Hemophilia A With Inhibitor

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with hemophilia A with inhibitors (Inhibitor titer; >0.5 Bethesda U/ml) Patients with agreement consents with the patients signatures Exclusion Criteria: Patients that do not fill the conditions described above
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Combination therapy<br>Effects of aPCC reaction in the presence of FVIII | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of coagulation effects using patients' plasmas by FXa/thrombin/plasmin generation tests and clot waveform analysis |  | up to 10 months | 
| Evaluation of coagulation effects using patients' whole bloods by ROTEM and T-TAS |  | up to 15 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hemophilia A, inhibitor, bypassing therapy, factor VIII
New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence

Study Overview
=================
Brief Summary
-----------------
In this study, mass spectrometry was used to analyze immune inflammation-related protein complexes, post-translational modified glycopeptide omics and tumor-related metabolomics in serum, respectively, in order to find potential metabolic small molecule biomarkers or marker profiles that can be used for early diagnosis of cancer recurrence.

Detailed Description
-----------------
Time cohort study: patients with confirmed ovarian epithelial cancer at different time cutoff points before treatment, after surgery, during chemotherapy, and after chemotherapy, until clinically confirmed patients relapse. At least 50 patients are expected to be enrolled.

Official Title
-----------------
New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence Via Analysis of Immunoinflammation-related Protein Complexes in Blood

Conditions
-----------------
Ovarian Cancer

Intervention / Treatment
-----------------
* Other: No intervention in clinical treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female A diagnosed patient with epithelial ovarian cancer Age ≤ 70 Exclusion Criteria: Male Suffering from other malignant tumors Non-compliant patient Age above 70

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention in clinical treatment|No intervention in clinical treatment|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immune Inflammation-Related Protein Complexes | The change of immune inflammation-related protein complexes | 2 years |